Slingshot members are tracking this event:
Celgene (CELG) Phase III data readout of AUGMENT trial testing Revlimid in treating relapsed and/or refractory Follicular lymphoma expected by end of 2017
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
|CELG||Community voting in process|
Slingshot Insights Explained
Jul 23, 2018
Don’t see a project related to the catalyst you care about?
Related Keywords Revlimid, Augment, Indolent Non-hodgkin Lymphoma, Phase 3 Study